Thursday, September 08, 2022 9:57:03 AM
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini.
Dear Fellow Stockholder,
Over the years we have been talking about the potential of buntanetap to treat more than Alzheimer's disease. In cell models, animal models and human clinical studies, we have seen that buntanetap works in numerous acute and chronic neurodegenerative conditions. I would like to take this opportunity to explain how one drug can be so broadly applicable.
Buntenatap works by inhibiting specific neurotoxic proteins such as amyloid precursor protein (APP), Tau, alpha-synuclein (aSYN), TAR DNA binding protein 43 (TDP-43), huntingtin (HTT) and prion protein. These proteins have normal functions but in their neurotoxic aggregating form, they impair axonal transport, slow synaptic transmission, cause inflammation, and ultimately, kill nerve cells, resulting in the loss of affected function in various neurodegenerative conditions.
The overexpression and aggregation of these proteins is caused by elevated levels of iron in the nerve cell. The mRNAs of neurotoxic aggregating proteins contain an iron response element (IRE) which binds to an iron regulatory protein called IRP1. At normal iron levels, translation occurs at appropriate physiological levels. When iron flows into the cell, the mRNAs are released and translated at higher rates by the ribosome. When massive iron flows in, the mRNAs remain unbound for as long as the iron is high and the proteins for these neurotoxic aggregating proteins are overexpressed. In this high iron situation, buntanetap binds to the atypical IRE-IRP1 complex and prevents the mRNA from being released and, therefore, from being translated and overexpressed.
Buntanetap is able to inhibit the translation of multiple neurotoxic proteins through this mechanism of action, and as a result has the potential to treat numerous acute and chronic neurodegenerative conditions that share this pathway. In mouse or rat models of Alzheimer's, Parkinson's, stroke, frontotemporal dementia, traumatic brain injury, glaucoma, and Down Syndrome, buntanetap has been shown to normalize the levels of these neurotoxic proteins and to restore function.
Most importantly, this has been demonstrated in human clinical trials. In our recent Phase 2 clinical trial in Alzheimer's disease and Parkinson's disease, treatment with buntanetap resulted in reduction of aggregating proteins and statistically significant improvement in motor function in Parkinson's disease patients and cognition in Alzheimer's disease patients.
FUNCTION
TEST
SUBJECT
ANIMALS
Memory, learning
Mazes
AD mice, DS mice, stroke mice, TBI rats
Movement
Colonic motility, grip strength
PD mice, tau mice
Vision
Sight
Glaucoma rats
Infections
Cell death
P. Gingivalis mice, Covid mice
HUMANS
Cognition, memory, learning
ADAScog11
Early AD patients
Attention, thinking speed
WAIS coding
Early AD patients
Movement, coordination
MDS-UPDRS
Early PD patients
Movement speed
WAIS coding
Early PD patients
Table 1: Summary of all animal and human study data.
We look forward to unlocking the full potential of buntanetap and addressing unmet needs across a range of acute and chronic neurological conditions.
Maria L. Maccecchini, Ph.D.,
Founder, President, CEO and Executive Board Member
Recent ANVS News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:03:33 PM
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 09:12:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:11:19 PM
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders • GlobeNewswire Inc. • 05/06/2024 11:30:00 AM
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/29/2024 02:10:00 PM
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters… • IH Market News • 02/28/2024 12:08:14 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:00:23 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:05:20 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:33:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:27:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:45:28 PM
- Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients • Business Wire • 11/02/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 04:28:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/01/2023 04:24:40 PM
- Annovis Bio Announces Pricing of $7.5 Million Public Offering • Business Wire • 10/31/2023 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/30/2023 09:27:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:17:25 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM